Full text

Turn on search term navigation

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Although around 80% of endometrial cancers are diagnosed at early stages and present with a 5-year survival rate exceeding 95%, patients with advanced and recurrent disease show a poor prognosis and low response rates to standard chemotherapy. In the era of targeted therapy, the great advances in the understanding of programmed death-ligand 1 (PD-L1) upregulation in cancer cells, which is responsible for tumor immune escape, have contributed to the increasing interest in immune checkpoint inhibitors as a promising strategy for the treatment of several refractory solid malignancies, including endometrial cancer. Several clinical trials have investigated the efficacy and safety of immune checkpoint inhibitors in endometrial cancer, which already led to the approval of the anti-programmed cell death protein 1 (anti-PD-1) antibody pembrolizumab as a satisfactory alternative for selected patients with unresectable or metastatic disease. As the future of cancer treatment will probably rely on combination therapy strategies, currently, innovative ongoing trials are exploring the potential role of immune checkpoint inhibitors associated with chemotherapy, radiotherapy, and other targeted therapies. Moreover, further research is warranted to discover new specific biomarkers that can accurately predict the response to immunotherapy.

Details

Title
Immune Checkpoint Inhibitors: A Promising Choice for Endometrial Cancer Patients?
Author
Musacchio, Lucia 1 ; Boccia, Serena Maria 1 ; Caruso, Giuseppe 1   VIAFID ORCID Logo  ; Santangelo, Giusi 1   VIAFID ORCID Logo  ; Fischetti, Margherita 1 ; Tomao, Federica 1 ; Perniola, Giorgia 1 ; Palaia, Innocenza 1   VIAFID ORCID Logo  ; Muzii, Ludovico 1   VIAFID ORCID Logo  ; Pignata, Sandro 2 ; Pierluigi Benedetti Panici 1 ; Violante Di Donato 1   VIAFID ORCID Logo 

 Department of Maternal and Child Health and Urological Sciences, University of Rome “Sapienza”, Policlinico “Umberto I”, 00161 Rome, Italy; [email protected] (L.M.); [email protected] (S.M.B.); [email protected] (G.S.); [email protected] (M.F.); [email protected] (F.T.); [email protected] (G.P.); [email protected] (I.P.); [email protected] (L.M.); [email protected] (P.B.P.); [email protected] (V.D.D.) 
 Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, 80131 Naples, Italy; [email protected] 
First page
1721
Publication year
2020
Publication date
2020
Publisher
MDPI AG
e-ISSN
20770383
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2641066148
Copyright
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.